Overview

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Meloxicam
Naproxen